|
|
|
The National Cancer Institute has awarded the University of Michigan Rogel Cancer Center a grant worth $37 million over five years. At the same time, the center’s designation as a “comprehensive cancer center” was renewed. The grant is a renewal of the Rogel Cancer Center’s support grant, provided as part of the NCI’s cancer centers program. Rogel first received NCI designation in 1988 and was designated comprehensive just three years later. The new grant provides funding through 2028, extending Rogel to 40 consecutive years of funding. The $36.7 million represents a 10% increase over the previous support grant.
|
The University of Michigan is developing two academic and scientific partnerships in Singapore that are expected to create opportunities for joint research, trainee and student exchange, and more. One of the partnerships is with the National University of Singapore’s Cancer Science Institute and the National University Cancer Institute, Singapore. The other partnership is between the U-M Rogel Cancer Center and the National Cancer Centre Singapore.
|
|
|
Germline genetic testing, in which inherited DNA is sequenced, is recommended for patients diagnosed with cancer to enable genetically targeted treatment and identify additional relatives who can benefit from personalized cancer screening and prevention. Not enough people are getting genetic testing for cancer, according to recent research.
|
Barriers to genetic testing for patients with cancer may vary based on demographics and other personal factors, a pilot project associated with a large clinical trial found. In a University of Michigan study, women, for instance, were more likely to report worries about the implications of their test results for family members and how their results could affect their health and life insurance.
|
Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds — and possibly streamline the diagnosis and treatment of gliomas, a study suggests.
|
Russell Ryan, M.D., an assistant professor in the Department of Pathology at the University of Michigan Medical School and a member of the University of Michigan Health Rogel Cancer Center, and his team used a method called ChIP-Seq to map the regulatory elements that control gene expression in B-cell lymphomas, a cancer of the immune system, in sample B-cell cancer cell lines.
|
|
|
|
MENU
